- Home
- LAZ vs BBIO Comparison
LAZ vs BBIO Comparison
Compare LAZ & BBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LAZ
- BBIO
- Stock Information
- Founded
- LAZ 1848
- BBIO 2015
- Country
- LAZ United States
- BBIO United States
- Employees
- LAZ N/A
- BBIO N/A
- Industry
- LAZ Investment Managers
- BBIO Biotechnology: Pharmaceutical Preparations
- Sector
- LAZ Finance
- BBIO Health Care
- Exchange
- LAZ Nasdaq
- BBIO Nasdaq
- Market Cap
- LAZ 5.1B
- BBIO 5.1B
- IPO Year
- LAZ 2005
- BBIO 2019
- Fundamental
- Price
- LAZ $52.04
- BBIO $26.49
- Analyst Decision
- LAZ Hold
- BBIO Strong Buy
- Analyst Count
- LAZ 7
- BBIO 13
- Target Price
- LAZ $52.29
- BBIO $47.92
- AVG Volume (30 Days)
- LAZ 880.8K
- BBIO 2.7M
- Earning Date
- LAZ 01-30-2025
- BBIO 11-12-2024
- Dividend Yield
- LAZ 3.84%
- BBIO N/A
- EPS Growth
- LAZ N/A
- BBIO N/A
- EPS
- LAZ 2.55
- BBIO N/A
- Revenue
- LAZ $3,047,514,000.00
- BBIO $217,765,000.00
- Revenue This Year
- LAZ $14.52
- BBIO $2,648.47
- Revenue Next Year
- LAZ $13.40
- BBIO N/A
- P/E Ratio
- LAZ $20.38
- BBIO N/A
- Revenue Growth
- LAZ 25.34
- BBIO 2209.77
- 52 Week Low
- LAZ $34.25
- BBIO $21.62
- 52 Week High
- LAZ $61.14
- BBIO $44.32
- Technical
- Relative Strength Index (RSI)
- LAZ 41.68
- BBIO 49.05
- Support Level
- LAZ $52.40
- BBIO $25.34
- Resistance Level
- LAZ $54.42
- BBIO $28.15
- Average True Range (ATR)
- LAZ 1.73
- BBIO 1.33
- MACD
- LAZ -0.59
- BBIO -0.24
- Stochastic Oscillator
- LAZ 31.78
- BBIO 24.73
About LAZ Lazard Inc.
Lazard has a storied history that can be traced back to 1848. The company's revenue is nearly equally split between financial advisory, such as acquisition and restructuring advisory, and asset management. The company's asset management business is primarily equities (over 80% of assets under management), has an international focus, and is geared toward institutional clients. By geography, the company earns approximately 60% of revenue in the Americas, 35% in EMEA, and 5% in Asia-Pacific. Lazard has offices across more than 20 countries and over 3,000 employees.
About BBIO BridgeBio Pharma Inc.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis) , is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.